What question did this study set out to answer?

To identify clinical, genomic, and measurable residual disease (MRD) predictors of relapse in pediatric B-cell acute lymphoblastic leukemia (B-ALL).

August 16, 2026CancersOpen Access

Pediatric B-Cell Acute Lymphoblastic Leukemia: Comprehensive Genomic Characterization Including SNP-Array and Analysis of Relapse Risk

View Full Paper

Ask AI

Bookmark

Authors

CPConcepción Prats‐Martín LOLauro Ortega ÁMÁgueda Molinos-Quintana

Discussion

Member takes

Overview

Cohort study finds high genetic risk and positive end-of-induction measurable residual disease predict relapse in pediatric B-ALL, highlighting improved risk stratification.

Key Points

To identify clinical, genomic, and measurable residual disease (MRD) predictors of relapse in pediatric B-cell acute lymphoblastic leukemia (B-ALL).
Followed 51 pediatric patients with B-ALL for a median duration of 30.5 months (IQR, 16–45.5).
Performed baseline genomic profiling using 2022 WHO/ICC criteria and SNP-arrays to detect copy number alterations in recurrent B-ALL genes (such as IKZF1, CDKN2A/B, and PAX5) and IKZF1plus status.
Assessed MRD via flow cytometry at day 15, day 33, and end of induction, evaluating relapse risk with Kaplan–Meier and Firth-penalized Cox regression models.
Relapse occurred in 11 patients and was significantly associated on univariate analysis with high cytogenetic risk (p = 0.007), >25% bone marrow blasts at day 15 (p < 0.001), and positive end-of-induction MRD (p = 0.017).
Multivariable analysis identified high genetic risk (HR = 9.31, 95% CI: 1.55–56.1, p = 0.010) and positive end-of-induction MRD (HR = 10.9, 95% CI: 2.39–49.9, p = 0.002) as independent predictors of relapse.

Cite This Study

Prats‐Martín et al. (2026) studied this question.

synapsesocial.com/papers/6a817a21f2fb91fc834adbfb https://doi.org/10.3390/cancers18162633

View Full Paper

Ask AI

Bookmark

August 16, 2026CancersOpen Access

Pediatric B-Cell Acute Lymphoblastic Leukemia: Comprehensive Genomic Characterization Including SNP-Array and Analysis of Relapse Risk

View Full Paper

Ask AI

Bookmark

Authors

CPConcepción Prats‐Martín LOLauro Ortega ÁMÁgueda Molinos-Quintana

Discussion

Member takes

Overview

Cohort study finds high genetic risk and positive end-of-induction measurable residual disease predict relapse in pediatric B-ALL, highlighting improved risk stratification.

Key Points

To identify clinical, genomic, and measurable residual disease (MRD) predictors of relapse in pediatric B-cell acute lymphoblastic leukemia (B-ALL).
Followed 51 pediatric patients with B-ALL for a median duration of 30.5 months (IQR, 16–45.5).
Performed baseline genomic profiling using 2022 WHO/ICC criteria and SNP-arrays to detect copy number alterations in recurrent B-ALL genes (such as IKZF1, CDKN2A/B, and PAX5) and IKZF1plus status.
Assessed MRD via flow cytometry at day 15, day 33, and end of induction, evaluating relapse risk with Kaplan–Meier and Firth-penalized Cox regression models.
Relapse occurred in 11 patients and was significantly associated on univariate analysis with high cytogenetic risk (p = 0.007), >25% bone marrow blasts at day 15 (p < 0.001), and positive end-of-induction MRD (p = 0.017).
Multivariable analysis identified high genetic risk (HR = 9.31, 95% CI: 1.55–56.1, p = 0.010) and positive end-of-induction MRD (HR = 10.9, 95% CI: 2.39–49.9, p = 0.002) as independent predictors of relapse.

Cite This Study

Prats‐Martín et al. (2026) studied this question.

synapsesocial.com/papers/6a817a21f2fb91fc834adbfb https://doi.org/10.3390/cancers18162633

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark